Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study

S. Soverini, L. Bavaro, C. de Benedittis, M. Martelli, A. Iurlo, N. Orofino, S. Sica, F. Sorà, F. Lunghi, F. Ciceri, S. Galimberti, C. Baratè, M. Bonifacio, L. Scaffidi, F. Castagnetti, G. Gugliotta, F. Albano, A.V.R. Rossi, F. Stagno, F. di RaimondoM. D'Adda, E. di Bona, E. Abruzzese, G. Binotto, R. Sancetta, M. Salvucci, I. Capodanno, M. Girasoli, S. Coluzzi, I. Attolico, C. Musolino, E. Calistri, M. Annunziata, M. Bocchia, S. Stella, A. Serra, S. Errichiello, G. Saglio, F. Pane, P. Vigneri, F. Mignone, M.A. Laginestra, S.A. Pileri, A. Percesepe, E. Tenti, G. Rosti, M. Baccarani, M. Cavo, G. Martinelli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)534-541
Number of pages8
JournalBlood
Volume135
Issue number8
DOIs
Publication statusPublished - 2020

Keywords

  • BCR ABL protein
  • BCR ABL1 protein
  • protein tyrosine kinase inhibitor
  • unclassified drug
  • adult
  • aged
  • Article
  • chronic myeloid leukemia
  • clinical decision making
  • feasibility study
  • gene mutation
  • genetic screening
  • health care cost
  • high throughput sequencing
  • human
  • major clinical study
  • mutational analysis
  • priority journal
  • prospective study
  • Sanger sequencing
  • treatment response
  • turnaround time

Cite this

Soverini, S., Bavaro, L., de Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., Galimberti, S., Baratè, C., Bonifacio, M., Scaffidi, L., Castagnetti, F., Gugliotta, G., Albano, F., Rossi, A. V. R., Stagno, F., ... Martinelli, G. (2020). Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study. Blood, 135(8), 534-541. https://doi.org/10.1182/blood.2019002969